NEUMORA THERAPEUTICS, INC. Total Shareholder Rtn Amt
NEUMORA THERAPEUTICS, INC. (NMRA) reported Total Shareholder Rtn Amt of $10.5 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-17.
Financial Statements › Notes
ecd:TotalShareholderRtnAmt · last filed 2026-04-17
| Period end | Total Shareholder Rtn Amt 12 month |
|---|---|
| 2025-12-31 | $10.50 DEF 14A · filed 2026-04-17 |
| 2024-12-31 | $62.17 DEF 14A · filed 2026-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |